Building a Global Patient Funnel to Predict Uptake for a Gene Therapy Across 15 Countries
Context: A global biotech developing an ex-vivo gene therapy for a rare neuromuscular disorder engaged Thelansis to build a cross-market patient funnel and uptake forecast. The therapy was approachin ...
Beyond the Drug: Why Ecosystem Based Commercial Models Are Becoming Critical in Rare Diseases
The quiet truth about rare disease medicines is that a brilliant molecule or a one-time gene therapy is only the opening act. Getting the drug from a lab bench miracle into durable, equitable patient ...
How Thelansis helped a Pharma company mitigate LOE impact through Forecast Modelling & Market Analytics
Background: In 2024, a mid-size specialty pharma company approached Thelansis with a clear challenge: its hero product, a second-line therapy in a tightly contested market, was set to enter Loss of E ...
Japan’s Evolving HTA Landscape: What Global Launch Teams Must Know
Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NH ...